EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Emerging Gene Therapy Approaches in the Management of Spinal Muscular Atrophy (SMA): An Overview of Clinical Trials and Patent Landscape

Aleksei S Ponomarev, Daria S Chulpanova iD, Lina M Yanygina, Valeriya V Solovyeva iD, Albert A Rizvanov iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms241813743 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Aleksei S Ponomarev und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia. Hauptthemen laut MEDLINE: Muscular Atrophy, Spinal. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kazan Federal University, KFU.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Spinal muscular atrophy (SMA) is a rare autosomal recessive neuromuscular disease that is characterized by progressive muscle atrophy (degeneration), including skeletal muscles in charge of the ability to move. SMA is caused by defects in the SMN1 gene (Survival of Motor Neuron 1) which encodes a protein crucial for the survival and functionality of neuron cells called motor neurons. Decreased level of functioning SMN protein leads to progressive degeneration of alpha-motor neurons performing muscular motility. Over the past decade, many strategies directed for SMN-level-restoration emerged, such as gene replacement therapy (GRT), CRISPR/Cas9-based gene editing, usage of antisense oligonucleotides and small-molecule modulators, and all have been showing their perspectives in SMA therapy. In this review, modern SMA therapy strategies are described, making it a valuable resource for researchers, clinicians and everyone interested in the progress of therapy of this serious disorder.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscular Atrophy, SpinalHumansMotor NeuronsGene EditingGenes, RegulatorGenetic TherapyRare Diseases

Stichwörter der Autor:innen

SMNclinical trialsgene therapypatent landscapespinal muscular atrophy

Autor:innen und Institutionen

  • Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.

ORCID-Profile: Daria S Chulpanova, Valeriya V Solovyeva, Albert A Rizvanov

Förderung

  • Kazan Federal University
  • KFU

Zitieren

APA

Ponomarev, A. S., Chulpanova, D. S., Yanygina, L. M., Solovyeva, V. V., & Rizvanov, A. A. (2023). Emerging Gene Therapy Approaches in the Management of Spinal Muscular Atrophy (SMA): An Overview of Clinical Trials and Patent Landscape. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241813743

Vancouver

Ponomarev AS, Chulpanova DS, Yanygina LM, Solovyeva VV, Rizvanov AA. Emerging Gene Therapy Approaches in the Management of Spinal Muscular Atrophy (SMA): An Overview of Clinical Trials and Patent Landscape. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241813743

BibTeX
@article{Ponomarev2023,
  author = {Ponomarev, Aleksei S and Chulpanova, Daria S and Yanygina, Lina M and Solovyeva, Valeriya V and Rizvanov, Albert A},
  title = {Emerging Gene Therapy Approaches in the Management of Spinal Muscular Atrophy (SMA): An Overview of Clinical Trials and Patent Landscape},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms241813743}
}
Kostenlos starten →